Dasatinib Tops Imatinib for Ph + Acute Lymphoblastic Leukemia
Four - year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Pharmacy, Journal, Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Chemotherapy | Gleevec | Leukemia | Pathology | Pediatrics